secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cibus, Inc. (CBUS)
CIK:        0001705843
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001628280-24-036131
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cibus reports Q2 net loss of $28.5M; cash $30M; sees runway into Q4 2024
------------------------------------------------------------------------

- Net loss of $28.5M ($1.14 loss per share) vs $20.5M loss in year-ago period (not comparable due to merger).
- Cash and cash equivalents $30M; expects to fund operations into Q4 2024 without additional financing.
- R&D expense $13.0M (+55% YoY); SG&A $9.3M (-16% YoY).
- Commercial progress: signed fourth rice HT trait customer FEDEARROZ; Wheat platform operational; Sclerotinia and NUE edits achieved in canola.
- Regulatory advances in Canada, UK, EU; IP expanded across 10 trait families.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1705843/000162828024036131/0001628280-24-036131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1705843/000162828024036131/cbus-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-036131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer